



Pharmaron Beijing Co., Ltd.

8th Floor, Block 1

6 Tai-He Road

Beijing Economic Technological Development Zone

Beijing, China

To: Citicorp International Limited (the *Trustee*)
20/F, Citi Tower, One Bay East
83 Hoi Bun Road, Kwun Tong
Kowloon Hong Kong

26 June 2023

Dear Sirs,

US\$300,000,000 Zero Coupon Convertible Bonds due 2026 convertible into ordinary H Shares of Pharmaron Beijing Co., Ltd. (康龍化成(北京)新藥技術股份有限公司) (the “Company”)(the “Bonds”)

This certificate is delivered to you in accordance with Clause 5.6 of the trust deed constituting the Bonds entered into between the Company and the Trustee on June 18, 2021 (the “**Trust Deed**”). Save as otherwise provided herein or unless the context otherwise requires, the terms used herein shall have the same meanings as contained in the Trust Deed.

I hereby certify that as a result of (i) the distribution of final dividends with respect to the year ended December 31, 2022 of RMB0.30 per share of the Company (the “**Shares**”)(the “**Final Dividends**”), and (ii) the issue of 5 capitalization Shares for every 10 Shares by way of capitalization of reserve (the “**Capitalization of Reserve**”) to the shareholders of the Company (the “**Shareholders**”) whose names appear on the register of members of the Company at the close of business on Wednesday, July 26, 2023 (being the record date for ascertaining the entitlement to the Final Dividends and the Capitalization of Reserve), which was approved by the Shareholders at the 2022 annual general meeting of the Company held on June 21, 2023, adjustments to the Conversion Price have to be made pursuant to clause 5.3.2 and 5.3.3 of the Conditions (the “**Adjustment**”).

In light of the Adjustment, the Conversion Price of the Bonds will be further adjusted from HK\$166.42 to HK\$110.32 (the “**Bonds Further Adjusted Conversion Price**”). Assuming full conversion of the outstanding Bonds at the Bonds Further Adjusted Conversion Price, the H Shares of the Company (the “**H Shares**”) that may be convertible and issuable under the outstanding Bonds will further increase from 13,986,540 H Shares to 21,098,984 H Shares. Such Adjustment will take effect on July 27, 2023.

The Adjustment is not subject to any calculation of consideration receivable under Clause 7.2(c) of the Trust Deed and therefore, no amount will be carried forward pursuant to Clause 7.2(c) of the Trust Deed.

This certificate is given without any personal responsibility.

For and on behalf of

PHARMARON BEIJING CO., LTD.

(康龍化成(北京)新藥技術股份有限公司)

A handwritten signature in black ink, consisting of stylized, overlapping letters and loops, positioned above a horizontal line.

Director